Clinical review: Goal-directed therapy-what is the evidence in surgical patients? The effect on different risk groups

Table 3 Complications by subgroup analysis

	Number of studies	Number of patients in GDT group	Patients with complications in GDT group (%)	Number of patients in control group	Patients with complications in control group (%)	Odds ratio	95% CI	P-value
Risk group
Intermediate risk	13	727	194(26.7)	698	288 (41.3)	0.43	0.27-0.67	0.0002
High risk	10	449	149 (33.2)	395	184 (46.6)	0.56	0.36-0.89	0.01
Extremely high risk	4	89	25 (28.1)	119	67 (56.3)	0.27	0.15-0.51	<0.0001
Fluid/inotropes
Fluid	12	610	198 (32.5)	636	299 (47.0)	0.47	0.30-0.73	0.0007
Fluid + inotrope	15	653	170 (26.0)	578	240 (41.5)	0.44	0.30-0.64	<0.0001
Goal
Supranormal	8	312	101 (32.4)	297	153 (51.5)	0.34	0.23-0.51	<0.00001
Normal	19	951	267 (28.1)	917	386 (42.1)	0.51	0.36-0.73	0.0002
Target
CI/DO2I	14	621	162 (26.1)	538	229 (42.6)	0.41	0.28-0.61	<0.0001
FTc/SV	7	361	118 (32.7)	392	180 (45.9)	0.50	0.30-0.84	0.009
Other	6	281	88 (31.3)	284	130 (45.8)	0.48	0.22-1.04	0.06
Type of monitor
PAC	10	441	99 (22.4)	391	129 (33.0)	0.49	0.30-0.80	0.005
ODM	6	316	92 (29.1)	347	150 (43.2)	0.46	0.25-0.86	0.01
Other	1!	506	177 (35.0)	476	260 (54.6)	0.41	0.26-0.64	0.0001

CI, cardiac index (ml/minute/m²); DO₂I, oxygen delivery index (ml/minute/m²); FTc, corrected flow time; ODM, oesophageal doppler monitor; PAC, pulmonary artery catheter; SV, stroke volume (ml)

ISSN: 1364-8535